Quality & compliance

  • Impending avalanche of regulatory compliance activity: Are you prepared?

    Impending avalanche of regulatory compliance activity: Are you prepared?

    View Now
  • How market exclusivities can affect your development program

    How market exclusivities can affect your development program

    Learn More
  • Parexel on the pulse2:08

    Parexel on the pulse

    Parexel regulatory expert, Mark Birse, gives an update on BREXIT.

    Watch Video
  • The Evolving Cell and Gene Therapy (CGT) Sector in China

    The Evolving Cell and Gene Therapy (CGT) Sector in China

    Learn More
  • Five points to remember if FDA issues a Form 483

    Five points to remember if FDA issues a Form 483

    Learn More
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Case Study Achieving Product Endorsement after a FDA Warning Letter

    Case Study Achieving Product Endorsement after a FDA Warning Letter

    View Now
  • Compliance Consulting Services Brochure for Law Firms

    Compliance Consulting Services Brochure for Law Firms

    View Now
  • How to interact virtually with health authorities

    How to interact virtually with health authorities

    View Now
  • GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

    GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

    As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

    Learn More
  • Risk Mitigation and Compliance Consulting Brochure for BioPharma Companies

    Risk Mitigation and Compliance Consulting Brochure for BioPharma Companies

    View Now
  • FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

    FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

    Global manufacturers and regulators are facing new challenges during the SARS-CoV-2 pandemic to maintain supply chains, and avoid shortages, of drugs, biologics and medical devices.  Numerous...

    Learn More
  • Navigating new steps in how FDA is managing COVID-19 Products

    Navigating new steps in how FDA is managing COVID-19 Products

    Learn More
  • Biosimilars in the time of COVID-19 and beyond

    Biosimilars in the time of COVID-19 and beyond

    Introduction The recent COVID-19 pandemic has triggered a race for pharmaceutical companies to repurpose their commercialized drugs approved for other clinical indications to treat patients...

    Learn More
  • Considerations for protecting your business and employees from COVID-19

    Considerations for protecting your business and employees from COVID-19

    This assessment highlights some planning considerations to help you maintain business operations, while protecting the safety of employees and customers during this pandemic.

    Learn More
  • Understanding the COVID-19 regulatory procedures the FDA is using

    Understanding the COVID-19 regulatory procedures the FDA is using

    A diagram that shows various procedural steps when interacting with the FDA through CTAP.

    Learn More
  • Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

    Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

    Learn More
  • Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products

    Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products

    At the recent 2019 Enforcement, Litigation and Compliance Conference hosted by the Food and Drug Law Institute (see here), Deputy Assistant Attorney General David Morrell delivered the...

    Learn More
  • What Influences the Compliance Culture at FDA?

    What Influences the Compliance Culture at FDA?

    The Office of Compliance (OC) in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) is a large organization.  It has hundreds of personnel who are...

    Learn More
  • FDA & Nitrosamine Impurities – The Proverb of the King with Long Arms

    FDA & Nitrosamine Impurities – The Proverb of the King with Long Arms

    If the dictionary is to be believed, the expression that kings have long arms was first listed as a proverb in 1539 (see here).  Over time it has developed into the commonly recognized idea...

    Learn More
  • As PIC/S expansion continues, what does this mean for manufacturers seeking to join?

    As PIC/S expansion continues, what does this mean for manufacturers seeking to join?

    Over the last few years the expansion of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) has continued at pace, with more Good Manufacturing Practice (GMP) Inspectorates joining,...

    Learn More
  • loading
    Loading More...